KESTRA MEDICAL TECHNOLOGIES, LTD.
Business
Kestra Medical Technologies is a commercial-stage wearable medical device company focused on cardiovascular disease management. It develops and commercializes the ASSURE Wearable Cardioverter Defibrillator (WCD), a wearable device that continuously monitors heart rhythms and delivers defibrillation therapy for life-threatening arrhythmias, supported by an integrated digital platform. The Cardiac Recovery System platform includes patient engagement applications, remote patient management tools, alert services, and emergency response coordination. The company sells its products directly to U.S. healthcare providers and payors through a contracted network of patient specialists and a direct sales force.
Summary from 10-K filed 2026-07-14
Financials
Consolidated Statement of Income
| Concept | Trend | Apr 30, 2026 2026-04-30 | Apr 30, 2025 2025-04-30 |
|---|---|---|---|
| Revenue | 95 | 60 | |
| Cost of revenue | 46 | 36 | |
| Gross profit | 49 | 24 | |
| Operating expenses: | — | — | |
| Research and development | 19 | 16 | |
| Selling, general and administrative | 164 | 115 | |
| Total operating expenses | 184 | 131 | |
| Loss from operations | −135 | −106 | |
| Other expense (income): | — | — | |
| Interest expense | 8 | 8 | |
| Interest income | 8 | 3 | |
| Other expense (income) | 3 | −3 | |
| Net loss before provision for income taxes | −131 | −114 | |
| Provision for income taxes | 294,000 | 135,000 | |
| Net loss | −132 | −114 | |
| Less: Undeclared preferred stock dividends | — | 12 | |
| Net loss attributable to common shareholders, basic | −132 | −126 | |
| Net loss attributable to common shareholders, diluted | −132 | −126 | |
| Net loss per share attributable to common shareholders, basic | −2.43 | −5.13 | |
| Net loss per share attributable to common shareholders, diluted | −2.43 | −5.13 | |
| Weighted average shares of common share outstanding, basic | 54 | 25 | |
| Weighted average shares of common share outstanding, diluted | 54 | 25 | |
| Other comprehensive loss: | — | — | |
| Net loss | −132 | −114 | |
| Unrealized loss on marketable securities | −218,000 | — | |
| Comprehensive loss | −132 | −114 |
Consolidated Balance Sheet
| Concept | Trend | Apr 30, 2026 2026-04-30 | Apr 30, 2025 2025-04-30 |
|---|---|---|---|
| Assets | — | — | |
| Current assets | — | — | |
| Cash and cash equivalents | 100 | 238 | |
| Short-term investments | 97 | — | |
| Accounts receivable, net | 15 | 8 | |
| Disposable medical equipment supplies | 7 | 7 | |
| Prepaid expenses and other current assets | 5 | 3 | |
| Total current assets | 222 | 255 | |
| Long-term investments | 66 | — | |
| Right-of-use assets | 3 | 2 | |
| Deposits | 2 | 2 | |
| Restricted cash | 334,000 | 334,000 | |
| Property and equipment, net | 59 | 35 | |
| Other long-term assets | 6 | 1 | |
| Total assets | 358 | 296 | |
| Liabilities and Shareholders' Equity | — | — | |
| Current liabilities | — | — | |
| Accounts payable | 27 | 24 | |
| Accrued liabilities | 23 | 14 | |
| Operating lease liabilities, current portion | 31,000 | 187,000 | |
| Total current liabilities | 50 | 38 | |
| Operating lease liabilities, net of current portion | 4 | 3 | |
| Warrant liabilities | 1 | 8 | |
| Other long-term liabilities | 306,000 | 140,000 | |
| Long-term debt, net | 43 | 41 | |
| Total liabilities | 99 | 90 | |
| Commitments and contingencies (Note 14) | — | — | |
| Redeemable preferred stock, $0.01 par value; 0 and 5,000,000 shares authorized as of April 30, 2025 and April 30, 2024, respectively; 0 and 177,110 shares issued and outstanding as of April 30, 2025 and April 30, 2024, respectively | — | — | |
| Shareholders' equity | — | — | |
| Common Shares, $1.00 par value; 100,000,000 shares authorized as of April 30, 2026 and April 30, 2025; 58,383,924 issued and outstanding as of April 30, 2026 and 51,348,656 shares issued and outstanding as of April 30, 2025 | 58 | 51 | |
| Additional paid-in capital | 853 | 674 | |
| Accumulated other comprehensive loss | −218,000 | — | |
| Accumulated deficit | −652 | −520 | |
| Total West Affum Intermediate Holdings Corp. stockholder's deficit | — | — | |
| Non-controlling interest | — | — | |
| Total shareholders' equity | 260 | 205 | |
| Total liabilities and shareholders' equity | 358 | 296 |
Consolidated Statement of Cash Flows
| Concept | Trend | Apr 30, 2026 2026-04-30 | Apr 30, 2025 2025-04-30 |
|---|---|---|---|
| Cash flows from operating activities | — | — | |
| Net loss | −132 | −114 | |
| Adjustments to reconcile net loss to net cash used in operating activities: | — | — | |
| Depreciation and amortization | 9 | 8 | |
| Loss on disposal of property and equipment | −1 | −1 | |
| Reserve for equipment and supplies | 2 | 754,000 | |
| Provision for uncollectible accounts receivable | 3 | 3 | |
| Amortization (accretion) of premiums (discounts) on securities, net | 106,000 | — | |
| Interest paid-in-kind | — | 855,000 | |
| Amortization of debt discounts and issuance costs | 2 | 1 | |
| Share-based compensation expense | 34 | 24 | |
| Non-cash lease expense | 326,000 | 416,000 | |
| Deferred income tax expense | 166,000 | 64,000 | |
| Non-cash loss on debt extinguishment | — | — | |
| Change in fair value of warrant liabilities | −3 | 3 | |
| Changes in operating assets and liabilities: | — | — | |
| Disposable medical equipment supplies | −458,000 | −3 | |
| Prepaid expenses and other current assets | 563,000 | 2 | |
| Accounts receivable | 9 | 9 | |
| Accounts payable | 4 | 3 | |
| Accrued liabilities | 8 | 5 | |
| Operating lease liabilities | −685,000 | 370,000 | |
| Other long-term assets | −40,000 | −40,000 | |
| Net cash used in operating activities | −82 | −78 | |
| Cash flows from investing activities | — | — | |
| Purchases of property and equipment | 35 | 23 | |
| Deposits for medical rental equipment | 528,000 | 655,000 | |
| Refund of deposits for medical rental equipment | 184,000 | 283,000 | |
| Investment in equity security | 5 | — | |
| Purchase of marketable securities | 163 | — | |
| Net cash used in investing activities | −203 | −23 | |
| Cash flows from financing activities | — | — | |
| Proceeds from issuance of redeemable preferred stock | — | 103 | |
| Proceeds from issuance of common stock | 149 | 216 | |
| Proceeds from issuance of stock to non-controlling interest | — | 17 | |
| Proceeds from issuance of long-term debt | — | — | |
| Proceeds from capital contributions | — | 2 | |
| Payment of debt issuance costs | — | — | |
| Repayment of long-term debt | — | — | |
| Payments of IPO offering costs | — | 4 | |
| Payment of equity issuance costs | 2 | 3 | |
| Deemed dividend for payments to third party on behalf of shareholder | 323,000 | 2 | |
| Proceeds from stock option exercises | 593,000 | — | |
| Net cash provided by financing activities | 147 | 330 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | −138 | 229 | |
| Cash, cash equivalents and restricted cash | — | — | |
| Beginning of period | 238 | 9 | |
| End of period | 100 | 238 | |
| Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets | — | — | |
| Cash and cash equivalents | — | — | |
| Restricted cash | — | — | |
| Cash, cash equivalents and restricted cash | — | — | |
| Non-cash investing and financing activities: | — | — | |
| Purchases of property and equipment in accrued liabilities and accounts payable | 8 | 7 | |
| Exercise of liability classified warrant | 4 | — | |
| Remeasurement of lease liability | 2 | — | |
| Equity offering costs incurred but not yet paid | 415,000 | 2 | |
| Deemed dividend for payments to third party on behalf of shareholder included in accrued liabilities and accounts payable | 172,000 | — | |
| Capital contribution from Parent to settle warrant obligation | — | — | |
| Capital contribution from West Affum LP to settle warrant obligation | — | — | |
| Issuance of warrants related to long term debt | — | 5 | |
| Conversion of redeemable preferred stock into Common Shares on completion of IPO | — | 281 | |
| Supplemental disclosure of cash flow information | — | — | |
| Income taxes paid | 13,000 | 83,000 | |
| Interest paid | 6 | 5 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is KESTRA MEDICAL TECHNOLOGIES, LTD.'s CIK number?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC CIK number is 0001877184 (1877184). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC filings?
All of KESTRA MEDICAL TECHNOLOGIES, LTD.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did KESTRA MEDICAL TECHNOLOGIES, LTD. last report earnings?
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) most recently filed an earnings 8-K with the SEC on Jul 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-303169). This is KESTRA MEDICAL TECHNOLOGIES, LTD.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is KESTRA MEDICAL TECHNOLOGIES, LTD.'s most recent earnings 8-K?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s latest earnings 8-K (Item 2.02) was filed Jul 14, 2026 under accession 0001193125-26-303169. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View KESTRA MEDICAL TECHNOLOGIES, LTD.'s latest earnings 8-K →
Look up any company's CIK number →